June 8, 2015ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)2,611 citationsOpen Access
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
View Full Paper
Key Points
- This research aims to evaluate the safety of sitagliptin regarding cardiovascular outcomes in patients with type 2 diabetes and existing cardiovascular disease.
- Randomized trial design with participants having type 2 diabetes and cardiovascular disease
- Received sitagliptin or usual care
- Trial registration number NCT00790205
- No increase in major adverse cardiovascular events observed in the sitagliptin group
- Heart failure hospitalization rates remained unchanged
- Additional adverse events did not differ significantly between groups
Abstract
Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events. (Funded by Merck Sharp TECOS ClinicalTrials.gov number, NCT00790205.).
Cite This Study
Green et al. (2015) studied this question.